Galsky MD - Search Results

1

Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.

Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Dreicer R, Chen YH, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Bellmunt J. Sonpavde G, et al. Among authors: galsky md. Clin Genitourin Cancer. 2015 Apr;13(2):185-92. doi: 10.1016/j.clgc.2014.09.004. Epub 2014 Oct 2. Clin Genitourin Cancer. 2015. PMID: 25458370

2

A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.

Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ. Rosenberg JE, et al. Among authors: galsky md. Cancer. 2006 Jan 1;106(1):58-62. doi: 10.1002/cncr.21559. Cancer. 2006. PMID: 16329138 Free article.

3

Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.

Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G, Bochner BH. Dash A, et al. Among authors: galsky md. Cancer. 2006 Aug 1;107(3):506-13. doi: 10.1002/cncr.22031. Cancer. 2006. PMID: 16773629 Free article.

4

Problems with the randomized discontinuation design.

Sonpavde G, Hutson TE, Galsky MD, Berry WR. Sonpavde G, et al. Among authors: galsky md. J Clin Oncol. 2006 Oct 1;24(28):4669-70; author reply 4670-1. doi: 10.1200/JCO.2006.08.1026. J Clin Oncol. 2006. PMID: 17008711 No abstract available.

5

Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.

Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF. Galsky MD, et al. Invest New Drugs. 2007 Jun;25(3):265-70. doi: 10.1007/s10637-006-9020-9. Epub 2006 Dec 5. Invest New Drugs. 2007. PMID: 17146733 Clinical Trial.

6

Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function.

Galsky MD, Iasonos A, Mironov S, Scattergood J, Boyle MG, Bajorin DF. Galsky MD, et al. Cancer. 2007 Feb 1;109(3):549-55. doi: 10.1002/cncr.22454. Cancer. 2007. PMID: 17200962 Free article. Clinical Trial.

7

Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials.

Hutson TE, Sonpavde G, Galsky MD. Hutson TE, et al. Among authors: galsky md. Clin Genitourin Cancer. 2006 Dec;5 Suppl 1:S31-9. doi: 10.3816/cgc.2006.s.005. Clin Genitourin Cancer. 2006. PMID: 17239282 Review.

8

Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.

Galsky MD, Iasonos A, Mironov S, Scattergood J, Donat SM, Bochner BH, Herr HW, Russo P, Boyle MG, Bajorin DF. Galsky MD, et al. Urology. 2007 Feb;69(2):255-9. doi: 10.1016/j.urology.2006.10.029. Urology. 2007. PMID: 17320659 Clinical Trial.

9

Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer.

Sonpavde G, Chi KN, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Berry WR, Kadmon D. Sonpavde G, et al. Among authors: galsky md. Cancer. 2007 Dec 15;110(12):2628-39. doi: 10.1002/cncr.23085. Cancer. 2007. PMID: 17941029 Free article. Review.

10

Germ-cell tumors.

Kondagunta V, Galsky MD, Sonpavde G. Kondagunta V, et al. Among authors: galsky md. N Engl J Med. 2007 Oct 25;357(17):1773; author reply 1773-4. N Engl J Med. 2007. PMID: 17969229 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

407 results

Search Page